And we all know how that turned out. Both have active clinical trials targeting Waldenstrom's. Baker Bros knows this as well. Remember the days when PCYC was $4?
But why? Why are big names buying so much IDRA? I don't get it. The only thing I can think of is - Crohn's Disease. If IDRA's TOL Inhibitors can be used to effectively treat Crohn's the market potential would be incredible. Maybe they know something we don't. But that's the only theory I have. Any others?
What do these guys know that we don't? Comments welcome?
Owner Name Date Shared Held Change (Shares) Change (%) Value (in 1,000s)
BAKER BROS. ADVISORS LP 03/31/2015 6,965,432 5,337,260 327.81 25,006
BROADFIN CAPITAL, LLC 03/31/2015 5,663,845 2,138,145 60.65 20,333
FMR LLC 03/31/2015 4,575,770 680,500 17.47 16,427
BLACKROCK FUND ADVISORS 03/31/2015 2,428,564 739,353 43.77 8,719
BLACKROCK INSTITUTIONAL TRUST COMPANY, N.A. 03/31/2015 1,942,504 1,042,904 115.93 6,974
PALO ALTO INVESTORS, LLC 03/31/2015 1,170,248 1,170,248 New 4,201
HEALTHCOR MANAGEMENT, L.P. 03/31/2015 1,165,786 357,494 44.23 4,185
ALYESKA INVESTMENT GROUP, L.P. 03/31/2015 1,005,067 1,005,067 New 3,608
Read more: http://www.nasdaq.com/symbol/idra/institutional-holdings#ixzz3cbOraGo2
A total paradigm shift in treating CHF. We're talking 2 Billion dollar market potential in less than a year after approval, and a marketplace worth close to 10 Billion dollars.
1+ billion dollar market cap and at least 2 years away from approval, means more dilution over the coming year. Seems over priced right now. No sign of revenue for 3 years. Comments?
It seems they are beginning to use Melafind in their Melanoma clinic. Doctors are saying the product is well designed and provides excellent clinical data for cataloging and mole assessment. If some of the best specialists in the world are using this system, there must be something good here. Market Cap seems very cheap for such a huge market with no competition.